Guardant Health Past Earnings Performance

Past criteria checks 0/6

Guardant Health's earnings have been declining at an average annual rate of -36.9%, while the Healthcare industry saw earnings growing at 5.5% annually. Revenues have been growing at an average rate of 26.9% per year.

Key information

-36.9%

Earnings growth rate

-28.6%

EPS growth rate

Healthcare Industry Growth8.5%
Revenue growth rate26.9%
Return on equity-302.1%
Net Margin-85.0%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Jan 21
With Guardant Health, Inc. (NASDAQ:GH) It Looks Like You'll Get What You Pay For

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Nov 20
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

Sep 26
Is There Now An Opportunity In Guardant Health, Inc. (NASDAQ:GH)?

A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Sep 05
A Look At The Fair Value Of Guardant Health, Inc. (NASDAQ:GH)

Is Guardant Health (NASDAQ:GH) A Risky Investment?

Aug 15
Is Guardant Health (NASDAQ:GH) A Risky Investment?

A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

May 28
A Look At The Intrinsic Value Of Guardant Health, Inc. (NASDAQ:GH)

Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Apr 05
Does Guardant Health (NASDAQ:GH) Have A Healthy Balance Sheet?

Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Dec 28
Is Guardant Health (NASDAQ:GH) Using Too Much Debt?

Guardant: Saving Lives One Blood Test At A Time

Oct 16

Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Aug 15
Here's Why Guardant Health (NASDAQ:GH) Can Afford Some Debt

Guardant Health's test gets FDA win for companion diagnostic to Enhertu's expanded use in lung cancer

Aug 12

Guardant Health: Recent Developments Signal More Upsides

Jul 31

Guardant Health: Pending Recession, May Hurt Cancer Care Demand

Jul 14

Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Apr 29
Guardant Health (NASDAQ:GH) Is Carrying A Fair Bit Of Debt

Guardant Health: Leaping Growth With Epic

Apr 14

Revenue & Expenses Breakdown
Beta

How Guardant Health makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

NasdaqGS:GH Revenue, expenses and earnings (USD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 23564-479451365
30 Sep 23536-432458385
30 Jun 23510-508474391
31 Mar 23482-665477387
31 Dec 22450-655464369
30 Sep 22431-606442338
30 Jun 22408-551420309
31 Mar 22391-419400287
31 Dec 21374-406399263
30 Sep 21344-409398230
30 Jun 21324-379390196
31 Mar 21298-336357168
31 Dec 20287-254299150
30 Sep 20271-185239135
30 Jun 20258-120183124
31 Mar 20245-77154107
31 Dec 19214-7614086
30 Sep 19184-7612877
30 Jun 19145-8711567
31 Mar 19111-9710259
31 Dec 1891-859051
30 Sep 1878-757442
30 Jun 1867-847635
31 Mar 1857-836929
31 Dec 1750-896626
31 Dec 1625-463611

Quality Earnings: GH is currently unprofitable.

Growing Profit Margin: GH is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: GH is unprofitable, and losses have increased over the past 5 years at a rate of 36.9% per year.

Accelerating Growth: Unable to compare GH's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: GH is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare industry (8%).


Return on Equity

High ROE: GH has a negative Return on Equity (-302.14%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.